StreetInsider.com News Articles

Form 10-Q MANGOCEUTICALS, INC. For: Mar 31

Tue, 19 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260519/26521756.html

Form 10-Q MANGOCEUTICALS, INC. For: Mar 31

Tue, 19 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260519/26521756.html

Form NT 10-Q MANGOCEUTICALS, INC. For: Mar 31

Fri, 15 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260515/26507107.html

Form NT 10-Q MANGOCEUTICALS, INC. For: Mar 31

Fri, 15 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260515/26507107.html

Form 10-K MANGOCEUTICALS, INC. For: Dec 31

Wed, 01 Apr 2026 06:31:00 -0400

http://archive.fast-edgar.com/20260401/AP2ZV22CZC2R79TD222J2ZY2QDI8ZZ22ZL82

Filed on: April 1, 2026

Form 10-K MANGOCEUTICALS, INC. For: Dec 31

Wed, 01 Apr 2026 06:31:00 -0400

http://archive.fast-edgar.com/20260401/AP2ZV22CZC2R79TD222J2ZY2QDI8ZZ22ZL82

Filed on: April 1, 2026

Form NT 10-K MANGOCEUTICALS, INC. For: Dec 31

Tue, 31 Mar 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260331/26252731.html

Form NT 10-K MANGOCEUTICALS, INC. For: Dec 31

Tue, 31 Mar 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260331/26252731.html

Form 4 MANGOCEUTICALS, INC. For: Mar 16 Filed by: Cohen Jacob D.

Fri, 20 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260320/26198464.html

Form 4 MANGOCEUTICALS, INC. For: Mar 16 Filed by: Cohen Jacob D.

Fri, 20 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260320/26198464.html

Form 4 MANGOCEUTICALS, INC. For: Jun 05 Filed by: Cohen Jacob D.

Fri, 20 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260320/26198469.html

Form 4 MANGOCEUTICALS, INC. For: Jun 05 Filed by: Cohen Jacob D.

Fri, 20 Mar 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260320/26198469.html

Mangoceuticals files $73 million lawsuit against former tech vendor

Tue, 17 Mar 2026 16:00:28 -0400

Mangoceuticals Inc. (NASDAQ: MGRX) filed a civil lawsuit in Texas state court seeking damages exceeding $73 million against Clarity Ventures Inc., its former technology consulting and software development firm.

The Dallas-based telemedicine company alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource planning and eCommerce platform that the firm was contracted to design and implement. The damages sought exclude interest, costs, and attorneys' fees.

Clarity has denied Mangoceuticals' allegations and filed counterclaims related to alleged unpaid invoices. Mangoceuticals stated it believes the counterclaims are unwarranted, asserting that all required payments under applicable agreements were made in full before ending

Mangoceuticals files $73 million lawsuit against former tech vendor

Tue, 17 Mar 2026 16:00:28 -0400

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Tue, 17 Mar 2026 16:00:00 -0400

Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has filed a civil lawsuit against Clarity Ventures, Inc., its former technology consulting and software development firm (“Clarity”).

The lawsuit, filed in Texas state court, seeks damages exceeding $73 million, exclusive of interest, costs, and attorneys’ fees. The Company alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Tue, 17 Mar 2026 16:00:00 -0400

Form 8-K MANGOCEUTICALS, INC. For: Mar 16

Tue, 17 Mar 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260317/26174634.html

Form 8-K MANGOCEUTICALS, INC. For: Mar 16

Tue, 17 Mar 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260317/26174634.html

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Fri, 06 Mar 2026 16:00:00 -0400

Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions and its partner IntraMont Technologies, Inc. today announced the filing of a Patent Cooperation Treaty (PCT) international application (P-641039-PC) on February 26, 2026, to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024.

This PCT filing directly extends the intellectual property

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Fri, 06 Mar 2026 16:00:00 -0400

This PCT filing directly extends the intellectual property

Form 8-K MANGOCEUTICALS, INC. For: Feb 23

Mon, 23 Feb 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260223/26043188.html

Form 8-K MANGOCEUTICALS, INC. For: Feb 23

Mon, 23 Feb 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260223/26043188.html

Mangoceuticals reports zero respiratory deaths in 29,000-bird trials

Mon, 23 Feb 2026 16:05:48 -0400

Mangoceuticals Inc. (NASDAQ: MGRX) announced that its antiviral compound MGX-0024 achieved zero respiratory-related mortality in field trials involving approximately 29,000 broiler chickens across three commercial farms in Tamil Nadu, India.

The birds received MGX-0024-infused drinking water from day 14 through market age without concurrent antibiotics or antivirals. Historical farm data indicated expected respiratory-related mortality of approximately 50%, which would have affected roughly 14,500 birds. All recorded deaths were attributed to non-respiratory causes, primarily heat stress.

A separate controlled study conducted at ICAR-National Institute of High Security Animal Diseases evaluated MGX-0024 against highly pathogenic H5N1 avian influenza. In the laboratory study, chicks that

Mangoceuticals reports zero respiratory deaths in 29,000-bird trials

Mon, 23 Feb 2026 16:05:48 -0400

Mangoceuticals reports zero respiratory deaths in 29,000-bird trials

Mon, 23 Feb 2026 16:05:48 -0400